Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Non-Current Deffered Revenue (2016 - 2019)

Enanta Pharmaceuticals' Non-Current Deffered Revenue history spans 8 years, with the latest figure at $900000.0 for Q3 2019.

  • For Q3 2019, Non-Current Deffered Revenue rose 51.77% year-over-year to $900000.0; the TTM value through Sep 2019 reached $900000.0, up 51.77%, while the annual FY2019 figure was $900000.0, 51.77% up from the prior year.
  • Non-Current Deffered Revenue reached $900000.0 in Q3 2019 per ENTA's latest filing, down from $923000.0 in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $923000.0 in Q2 2019 to a low of $161000.0 in Q1 2015.
  • Average Non-Current Deffered Revenue over 5 years is $650789.5, with a median of $674000.0 recorded in 2018.
  • Peak YoY movement for Non-Current Deffered Revenue: surged 322.22% in 2015, then decreased 14.06% in 2018.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $646000.0 in 2015, then increased by 8.51% to $701000.0 in 2016, then fell by 6.7% to $654000.0 in 2017, then increased by 3.06% to $674000.0 in 2018, then surged by 33.53% to $900000.0 in 2019.
  • Per Business Quant, the three most recent readings for ENTA's Non-Current Deffered Revenue are $900000.0 (Q3 2019), $923000.0 (Q2 2019), and $842000.0 (Q1 2019).